Patients Coming Off Slimming Jabs Gain Back Weight Far More Rapidly Than Dieters

Fresh analysis reveals that patients who come off popular GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who halt traditional lifestyle programs.

Research printed in a leading health publication demonstrates that while overweight people frequently drop a large proportion of their total mass while undergoing treatment, the mass returns at an average rate of nearly a kilo each month after stopping.

"Users buying such treatments need to be cognizant of the risk of quick rebound weight gain when the therapy concludes," warns expert Dr. Susan Jebb.

This pace of recovery implies a reversion to pre-treatment weight in about one and a half years.

Analyzing Treatments

The study, which looked at dozens of trials involving over 9,000 of patients, compared the outcomes of these new drugs with older methods.

Researchers point out that individuals who lose weight through diet and exercise generally see a slower creep back—approximately 0.1 kg a month—once they finish.

Understanding the Rapid Regain

Experts believe the mode of action of the jabs accounts for the amplified weight return.

GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which controls appetite.

"Long-term administration of the hormone levels several times higher than the body's typical production may cause the system to generate a reduced amount of its own natural GLP-1, and may also reduce sensitivity to its actions," said Dr. Adam Collins, a nutrition expert.

"Withdrawal of this hormone supplement results in hunger is uncontrolled, making binge eating much more probable."

An Ongoing Disease?

Health authorities recommend the injections for individuals with weight-linked medical conditions, alongside recommended lifestyle changes.

Professionals contend that, due to the high risk of relapse, the treatment might need to be long-term.

This perspective is echoed by pharmaceutical companies, who state that the results "emphasize the long-term nature of obesity," akin to managing diseases like diabetes.

Patient Testimonies

People who have come off the jabs describe a intense return of appetite.

"It was like something that goes on and I was suddenly ravenous," recalled an individual.

The struggle is worsened if patients have not adopted lasting lifestyle or habit changes during treatment.

Widespread Adoption

Figures suggest that a significant number of adults in the UK have used weight-loss jabs in the past year, with desire continuing to grow.

• Adoption is greater among females than males.
• The middle-aged age group shows the highest usage rates.
• Many access the medications through private healthcare rather than public health services.

Finally, clinicians emphasize that while GLP-1 drugs are potent agents for weight loss, they are not a standalone fix and lasting health benefits relies on integrated behavioural changes.